An expert panel of gynecologic oncologists reviews recent data from the 2023 ASCO Annual Meeting and discusses the evolving treatment landscape.
June 29th 2023
A panel of expert gynecologic oncologists introduce themselves and review frontline maintenance treatment options in ovarian cancer.
Experts on ovarian cancer discuss germline and somatic testing practices and provide clinical insights on factors that influence treatment decisions.
July 6th 2023
An expert panel highlights current unmet needs in the maintenance setting for ovarian cancer.
A comprehensive overview of recent clinical trial data on PARP inhibitors in the first-line maintenance setting in ovarian cancer presented at ASCO 2023.
July 13th 2023
Ovarian cancer experts review clinical trial data on the efficacy of later-line therapies in advanced ovarian cancer.
A detailed discussion focused on recent data on PARP inhibitors in the recurrent ovarian cancer setting.
July 20th 2023
A panel of experts on ovarian cancer review ongoing trials on maintenance therapies for recurrent ovarian cancer.
Expert gynecologic oncologists react to data from the MIRASOL trial, which studied mirvetuximab in patients with platinum-resistant ovarian cancer.
July 27th 2023
The expert panel switches its focus to endometrial cancer and discusses recent data from clinical trials.
Experts on endometrial cancer review the NRG-GY018 and RUBY clinical trials.
August 3rd 2023
A panel of gynecologic oncologists review the PHAEDRA study and discuss the overall treatment landscape for endometrial cancer.
The expert panel reviews the KEYNOTE-775 trial, which focused on lenvatinib and pembrolizumab in advanced endometrial cancer.
August 10th 2023
An overview of ongoing research in the endometrial cancer treatment space.
The panel looks to the future and offers closing thoughts on the evolving treatment landscape in endometrial cancer.